Two-pronged Attack on Neuroblastoma
How inhibiting both polyamine synthesis (with DFMO) and uptake (with new small molecule AMXT 1501) could delay tumor development.
Jonathan James | | Quick Read
The MYCN oncogene – highly upregulated in neuroblastoma – has long been regarded as an attractive target for therapy, but successful translation into the clinic has proven challenging (1). Attention thus turned to downstream pathways and, now, a multinational team of researchers has demonstrated the feasibility of targeting two aspects of a crucial pathway in cancer growth: polyamine synthesis and uptake (2).
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts